Description
Aranesp (Darbepoetin Alpha) Solution for Injections 100 mcg/ml Syringe 0.3 ml №1
Ingredients
Active Ingredient: Darbepoetin Alpha
Other Ingredients: Sodium Phosphate Monobasic Monohydrate, Sodium Phosphate Dibasic Anhydrous, Polysorbate 80, and Water for Injection.
Dosage
The Recommended Dosage: The dosage of Aranesp depends on the patient’s condition and response to treatment. It is usually administered as a subcutaneous injection once weekly or once every 2 weeks. The dosage may vary from patient to patient, so follow your healthcare provider’s instructions carefully.
Indications
Aranesp is indicated for:
- Treatment of anemia in patients with chronic kidney disease
- Reduction of transfusion requirements in patients undergoing elective surgery
Contraindications
Do not use Aranesp if:
- You have uncontrolled hypertension
- You have pure red cell aplasia that begins after treatment with Aranesp or other erythropoietin protein drugs
Directions
- Aranesp is for subcutaneous injection only.
- Do not shake the syringe.
- Follow proper injection techniques as instructed by your healthcare provider.
Scientific Evidence
Pharmacological Effects: Aranesp works by stimulating the bone marrow to produce more red blood cells, thus increasing the oxygen-carrying capacity of the blood. This can help improve symptoms of anemia and reduce the need for blood transfusions in certain patients.
Clinical Trials: Clinical studies have shown that Aranesp is effective in treating anemia associated with chronic kidney disease and in reducing transfusion requirements in patients undergoing surgery. For example, a study published in the New England Journal of Medicine demonstrated that darbepoetin alpha effectively increased hemoglobin levels in patients with chronic kidney disease.
Overall, Aranesp has been shown to be a safe and effective treatment option for managing anemia in various clinical settings.
Additional Information
- Store Aranesp in the refrigerator at 2°C to 8°C. Do not freeze.
- Keep the medication out of reach of children.
- Check the product for particles or discoloration before use.
In conclusion, Aranesp (Darbepoetin Alpha) is a valuable medication for managing anemia in patients with chronic kidney disease and reducing transfusion requirements in surgical patients. Its pharmacological effects on red blood cell production have been well-documented in clinical trials, making it a trusted option for healthcare providers. Always follow your healthcare provider’s instructions for the correct dosage and administration of Aranesp.
